Compare Amphastar Pharmaceuticals Inc (AMPH) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Microchip Technology Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Microchip Technology Inc. trades at $85.76 (market cap $48.11B). The key difference: Microchip Technology Inc. is far larger — about 58.2× Amphastar Pharmaceuticals Inc's market cap, and Microchip Technology Inc. pays a 2.05% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MCHP | |
|---|---|---|
Market Cap | $826.08M | $48.11B |
Sector | Health | Technology |
52-Week High | $30.81 | $102.97 |
52-Week Low | $16.87 | $49.02 |
Enterprise Value | $1.22B | $53.40B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Microchip Technology (MCHP) trades at $88.59, up 0.37% with a bearish technical signal despite recent earnings beats. The stock shows elevated valuation ratios (P/E 402.68, P/S 10.25) amid weak 2025 profitability (net income margin -0.02%), though 2026 forecasts suggest recovery. Recent news highlights AI-driven semiconductor demand and new product launches in aerospace/defense. Cash flow improved to $452M in 2025, but debt remains high at $5.63B.
Outlook: Analyst consensus is strongly bullish (68% buy ratings) with a $115.45 price target, citing AI momentum and cyclical recovery. Risks include high debt, volatile earnings, and sensitivity to semiconductor cycles. The stock offers growth exposure to data center and auto markets but requires monitoring of margin improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
